ECM-Coated Nanoparticles for Lung Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhalational drug delivery methods face challenges in maximizing deposition and uptake of nanoparticles at the alveolar air-tissue interface due to ventilation cycles, mucociliary clearance, alveolar fluid lining, and macrophage phagocytosis, resulting in only 20-30% of inhaled nanoparticles reaching lung cells effectively.
Innovation Solution
Development of nanoparticles coated with decellularized extracellular matrix (ECM), specifically lung-derived ECM, which enhances uptake and retention in lung cells, delays payload release, and improves pharmacokinetics when delivered via inhalation, using PLGA nanoparticles coated via physical adsorption or layer-by-layer techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nanoparticles are delivered via inhalation to reach alveolar cells, then drug delivery to lung tissue is achieved, but only 20-30% of nanoparticles are effectively taken up due to mucociliary clearance, alveolar fluid lining, and macrophage phagocytosis
Solution Approach 1:
The patent uses extracellular matrix (ECM) as an intermediary coating on nanoparticle surfaces to mediate interactions with alveolar epithelial cells. This ECM layer helps nanoparticles evade macrophage detection and phagocytosis while facilitating uptake by target cells, thereby improving delivery efficiency and reducing nanoparticle loss in the lung environment
Solution Approach 2:
The patent modifies nanoparticle surface properties by coating with ECM proteins, which changes the physical and chemical parameters of the nanoparticle surface. This surface modification alters how nanoparticles interact with lung tissue components, improving cellular uptake and reducing clearance by macrophages and mucociliary systems
2Area of stationary object
If nanoparticles are made smaller than 2 μm to concentrate in alveoli, then alveolar deposition is improved, but uptake by alveolar epithelial cells becomes more challenging due to rapid clearance
Solution Approach 1:
The ECM coating acts as a mediator that extends nanoparticle retention time in the lung by facilitating longer interaction with alveolar epithelial cells. The coating enables nanoparticles to remain in the alveolar region long enough for effective cellular uptake while preventing rapid clearance by macrophages and mucociliary mechanisms
Solution Approach 2:
The ECM coating is applied preliminarily to nanoparticle surfaces before inhalation delivery. This pre-coating prepares the nanoparticles to interact favorably with lung tissue, enabling them to maintain presence in the alveolar region long enough for therapeutic effect while avoiding rapid clearance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ECM-coated nanoparticles demonstrate increased cellular uptake, delayed release, and prolonged therapeutic effects, with GFP expression peaking by 10-14 days and declining thereafter, indicating improved drug delivery and retention in lung tissues.
Implementation Method 1
The ECM was coated onto nanoparticle surface by physical adsorption
Implementation Method 2
ECM-coated nanoparticles loaded with hEPOR-GFP cDNA were aerosolized and delivered into rat lung
Data Source
AI summary
Nanoparticles coated with extracellular matrix (ECM) are provided, in some aspects, for the delivery of a therapeutic protein, nucleic acid, or drug. In some embodiments, the nanoparticles are delivered to a subject via inhalation or aerosol delivery. Also provided, in some aspects, are methods for treating acute lung injury comprising administering α-Klotho (αKlotho) protein or DNA to a subject.